ClinicalTrials.gg
CompletedNCT07944339Updated Nov 18, 2026

Automated Pupillometry for Diabetic Retinopathy Screening

An observational study in Diabetic Retinopathy and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Chile. Completed at 1 site in Chile. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Chile · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
240
Ages
30 Years to 75 Years
Sex
All
01

Study summary

The goal of this observational study is to learn if automated pupillometry (AP)-a simple tool that measures how the eye responds to a brief light stimulus-can help diagnose diabetic retinopathy (DR), a complication of diabetes that can lead to blindness, in people with type 2 diabetes (T2DM).

The main question it aims to answer is:

  • How accurate is AP for screening DR in people with T2DM?

DR usually has no symptoms in its early stages, so early screening is crucial to prevent progression to blindness. Participants in this study will undergo two tests:

  • AP, which measures the eye's response to light.
  • A fundoscopic examination (FE), which is the current test used to diagnose DR. FE is performed by an ophthalmologist, making it more expensive and harder to access due to long waiting lists. These challenges mean not all people with diabetes can have this test annually, as recommended. AP could offer a cheaper and more accessible option that doesn't require a specialist, potentially reducing waiting times and enabling earlier diagnosis of DR in people with diabetes.
Read the detailed description

Patients will undergo a clinical evaluation, AP assessment, and FE during the same visit. AP will be performed to obtain three valid trials per eye using a clinical pupilometer. For DR diagnosis, pupil-dilated eye fundus images will be captured with a retinal camera and subsequently interpreted by an ophthalmologist. Both patients and AP/FE operators will remain blinded to the FE/AP data.

02

Conditions studied

  • Diabetic Retinopathy
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Diabetic Retinopathy
  • Screening
  • Automated Pupillometry
  • Type 2 Diabetes Mellitus
  • Fundoscopic examination
  • Primary Health Care
03

In context

Diabetic Retinopathy

781 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

This study's enrollment of 240 is above the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

University of Chile is the lead sponsor of 195 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with type 2 diabetes (T2DM) from all three public primary care health centers in the municipality of Independencia (Santiago, Chile), who are on the waiting list for fundoscopic examination (FE) to screen for diabetic retinopathy (DR).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult between 30 and 75 years old.
  • Diagnosis of T2DM made by a doctor according to the criteria indicated in the Explicit Health Guarantee Guide (GES) for T2DM (based on fasting blood glucose, oral glucose tolerance test or random blood glucose test in symptomatic subjects).
  • Native or conversational proficiency in Spanish.
  • Be under control in the Cardiovascular Health Program (PSCV) with at least two consultations registered since admission, or have entered the PSCV in the last six months.
  • Have a landline or mobile phone available to be contacted.

Exclusion criteria

Exclusion Criteria:

  • Hospitalization and/or any recent acute illness (less than one month) that required medical attention.
  • History of any of the following diseases: non-diabetic retinopathy, blindness, deafness, oncological disease not cured or under active treatment, neurodegenerative disease, advanced cirrhosis ( B or C), uncompensated heart failure, acute stress disorder.
  • Ingestion of alcohol or recreational drugs within 8 hours prior to the Automated Pupillometry (AP) exam.
  • Dependency in basic activities of daily living.
  • Pregnancy.
  • Afro-American ancestry (greater activation of sympathetic tone in this population, which modifies pupillary reactivity).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
240 participants (actual)
Patient registry
No

Groups and cohorts

  • With Diabetic Retinopathy

    Patient with diabetic retinopathy diagnosed through fundoscopic examination

  • Without Diabetic Retinopathy

    Patient without diabetic retinopathy on fundoscopic examination.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of automated pupillometry (AP) for diabetic retinopathy (DR) screening

    The diagnostic accuracy of AP for DR will be evaluated by the area under the curve (AUC), sensitivity, specificity and predictive values.

    Time frame: At baseline (study enrollment)

Secondary outcomes

  1. Prevalence of diabetic retinopathy in the study sample

    Frequency (%) of participants with diabetic retinopathy in the sample

    Time frame: At baseline (study enrollment)

  2. Risk factors for diabetic retinopathy

    Clinical factors statistically related with diabetic retinopathy presence

    Time frame: At baseline (study enrollment)

07

Study locations

1 site
  • Primary Care Ophthalmology Unit
    Santiago, Chile
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Aug 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartActual
Jan 26, 2023
Primary completionActual
Aug 18, 2023
CompletionActual
Jan 31, 2024
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944339
Collaborators
National Fund for Research and Development in Health, Chile, ANID
Responsible party
Abraham Gajardo Cortez (Assistant Professor, University of Chile) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 26, 2023
Primary completion
Aug 18, 2023
Completion
Jan 31, 2024
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion